Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARGX argenex	$722.01 +2.2%	$620.60	$510.05 ▼ $723.28	$43.59B	0.41	358,458 shs	468,113 shs
GMAB Genmab A/S	$27.08 +4.6%	$22.54	$17.24 ▼ $27.91	$15.96B	0.93	1.27 million shs	2.32 million shs
ONC BeOne Medicines	$336.26 +1.3%	$287.95	$170.99 ▼ $339.86	$33.54B	0.21	311,201 shs	556,401 shs
TAK Takeda Pharmaceutical	$15.15 -0.1%	$14.82	$12.80 ▼ $15.56	$48.24B	0.22	3.03 million shs	3.69 million shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARGX argenex	+2.21%	+1.98%	+4.59%	+24.36%	+40.41%
GMAB Genmab A/S	+4.60%	+9.28%	+23.20%	+24.16%	-1.20%
ONC BeOne Medicines	+1.27%	+12.03%	+10.50%	+30.84%	+33,625,999,900.00%
TAK Takeda Pharmaceutical	-0.13%	+1.88%	+6.17%	+1.14%	+1.51%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARGX argenex	3.9972 of 5 stars	2.5	3.0	0.0	3.3	1.7	4.4
GMAB Genmab A/S	3.9575 of 5 stars	3.3	5.0	0.0	2.9	0.0	3.1
ONC BeOne Medicines	0.8016 of 5 stars	1.5	0.0	0.0	2.7	1.7	0.6
TAK Takeda Pharmaceutical	2.457 of 5 stars	0.0	4.0	2.5	2.2	0.0	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARGX argenex	3.09	Buy	$772.84	7.04% Upside
GMAB Genmab A/S	2.64	Moderate Buy	$37.60	38.85% Upside
ONC BeOne Medicines	3.00	Buy	$330.89	-1.60% Downside
TAK Takeda Pharmaceutical	2.00	Hold	N/A	N/A

Current Analyst Ratings Breakdown

Latest GMAB, TAK, ARGX, and ONC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/2/2025	ARGX argenex	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$880.00 ➝ $887.00
8/26/2025	ARGX argenex	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$818.00
8/26/2025	ARGX argenex	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$750.00 ➝ $820.00
8/25/2025	ARGX argenex	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$800.00
8/25/2025	ARGX argenex	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$850.00
8/21/2025	TAK Takeda Pharmaceutical	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
8/19/2025	GMAB Genmab A/S	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/15/2025	GMAB Genmab A/S	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$35.00 ➝ $36.00
8/7/2025	ONC BeOne Medicines	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$349.00 ➝ $364.00
8/7/2025	ONC BeOne Medicines	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$350.00 ➝ $365.00
8/4/2025	ARGX argenex	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$775.00 ➝ $830.00

(Data available from 9/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARGX argenex	$2.25B	19.62	$3.01 per share	239.76	$99.60 per share	7.25
GMAB Genmab A/S	$3.12B	5.56	$1.65 per share	16.40	$8.26 per share	3.28
ONC BeOne Medicines	$3.81B	9.67	N/A	N/A	$34.40 per share	9.78
TAK Takeda Pharmaceutical	$30.09B	1.60	$3.22 per share	4.71	$14.89 per share	1.02

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARGX argenex	$833.04M	$19.50	37.03	66.54	0.81	40.98%	21.06%	18.25%	10/30/2025 (Estimated)
GMAB Genmab A/S	$1.14B	$1.99	13.61	15.21	7.22	37.53%	21.03%	16.98%	11/5/2025 (Estimated)
ONC BeOne Medicines	-$644.79M	-$1.73	N/A	473.61	N/A	-3.89%	-1.22%	-0.72%	N/A
TAK Takeda Pharmaceutical	$712.33M	$0.30	50.48	9.18	N/A	3.20%	10.50%	5.10%	10/30/2025 (Estimated)

Latest GMAB, TAK, ARGX, and ONC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	GMAB Genmab A/S	$0.39	$0.54	+$0.15	$0.54	$5.77 billion	$925.00 million
8/6/2025	Q2 2025	ONC BeOne Medicines	$0.48	$0.84	+$0.36	$0.84	$1.24 billion	$1.32 billion
7/31/2025	Q2 2025	ARGX argenex	$2.84	$3.74	+$0.90	$3.74	$776.82 million	$866.79 million
7/30/2025	Q1 2026	TAK Takeda Pharmaceutical	$0.47	$0.52	+$0.05	$0.27	$7.96 billion	$7.45 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARGX argenex	N/A	N/A	N/A	N/A	N/A
GMAB Genmab A/S	N/A	N/A	N/A	N/A	N/A
ONC BeOne Medicines	N/A	N/A	N/A	N/A	N/A
TAK Takeda Pharmaceutical	$0.55	3.63%	N/A	183.33%	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARGX argenex	N/A	5.60	5.27
GMAB Genmab A/S	N/A	6.22	6.20
ONC BeOne Medicines	0.04	1.95	1.72
TAK Takeda Pharmaceutical	0.60	1.16	0.59

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARGX argenex	60.32%
GMAB Genmab A/S	7.07%
ONC BeOne Medicines	48.55%
TAK Takeda Pharmaceutical	9.17%

Insider Ownership

Company	Insider Ownership
ARGX argenex	2.43%
GMAB Genmab A/S	1.54%
ONC BeOne Medicines	6.62%
TAK Takeda Pharmaceutical	0.04%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARGX argenex	1,599	61.20 million	59.71 million	Optionable
GMAB Genmab A/S	2,682	641.59 million	631.71 million	Optionable
ONC BeOne Medicines	11,000	109.60 million	102.34 million	N/A
TAK Takeda Pharmaceutical	47,455	3.18 billion	3.18 billion	Optionable

GMAB, TAK, ARGX, and ONC Headlines

Recent News About These Companies

Novartis thinks Arrowhead brain drug can succeed where others couldn’t

September 2 at 12:52 PM | biopharmadive.comB

Northern Trust Corp Sells 233,675 Shares of Takeda Pharmaceutical Co. $TAK

September 2 at 3:57 AM | marketbeat.com

Takeda Pharmaceutical Co. $TAK Stock Holdings Increased by Russell Investments Group Ltd.

September 1 at 3:41 AM | marketbeat.com

Takeda Pharmaceutical Co. $TAK Shares Bought by Charles Schwab Investment Management Inc.

August 31, 2025 | marketbeat.com

Capital Fund Management S.A. Acquires New Shares in Takeda Pharmaceutical Co. $TAK

August 29, 2025 | marketbeat.com

Takeda Pharmaceutical Company Limited (TAK) Advances γδ T Cell Cancer Treatments

August 28, 2025 | insidermonkey.com

HighTower Advisors LLC Sells 36,694 Shares of Takeda Pharmaceutical Co. $TAK

August 28, 2025 | marketbeat.com

Mass. biopharma industry loses jobs, hits lowest level of funding in years

August 26, 2025 | wbur.orgW

Rusfertide Receives Breakthrough Therapy Designation for Treatment of Erythrocytosis in Patients with Polycythemia Vera

August 25, 2025 | miamiherald.comM

Takeda Pharmaceutical (NYSE:TAK) Lowered to Strong Sell Rating by Zacks Research

August 25, 2025 | marketbeat.com

Ionis steps into crowded HAE market with FDA approval for Dawnzera

August 23, 2025 | fiercepharma.comF

Takeda eyes India for global clincal trials amid booming clinical trials market

August 23, 2025 | medicaldialogues.inM

Japanese pharma company Takeda to conduct clinical trials in India soon

August 22, 2025 | msn.com

Takeda Pharmaceutical (NYSE:TAK) Reaches New 12-Month High - Should You Buy?

August 22, 2025 | marketbeat.com

Myasthenia Gravis Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Alpine Immune Science, Toleranzia, Cabaletta Bio, Rallybio, Alexion ...

August 21, 2025 | theglobeandmail.com

Japan's Takeda weighs India for global trials to speed up drug launches

August 21, 2025 | reuters.com

Short Interest in Takeda Pharmaceutical Co. (NYSE:TAK) Rises By 81.5%

August 20, 2025 | marketbeat.com

Corient IA LLC Purchases Shares of 40,000 Takeda Pharmaceutical Co. (NYSE:TAK)

August 19, 2025 | marketbeat.com

Ethic Inc. Reduces Stake in Takeda Pharmaceutical Co. (NYSE:TAK)

August 19, 2025 | marketbeat.com

Boston Partners Raises Stake in Takeda Pharmaceutical Co. (NYSE:TAK)

August 19, 2025 | marketbeat.com

US Bancorp DE Trims Position in Takeda Pharmaceutical Co. (NYSE:TAK)

August 10, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

GMAB, TAK, ARGX, and ONC Company Descriptions

argenex NASDAQ:ARGX

$722.01 +15.60 (+2.21%)

Closing price 09/3/2025 04:00 PM Eastern

Extended Trading

$719.76 -2.26 (-0.31%)

As of 09/3/2025 07:58 PM Eastern

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

Genmab A/S NASDAQ:GMAB

$27.08 +1.19 (+4.60%)

Closing price 09/3/2025 04:00 PM Eastern

Extended Trading

$27.08 +0.01 (+0.02%)

As of 09/3/2025 07:33 PM Eastern

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

BeOne Medicines NASDAQ:ONC

$336.26 +4.22 (+1.27%)

As of 09/3/2025 04:00 PM Eastern

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

Takeda Pharmaceutical NYSE:TAK

$15.14 -0.02 (-0.10%)

Closing price 09/3/2025 03:59 PM Eastern

Extended Trading

$15.16 +0.01 (+0.07%)

As of 09/3/2025 06:25 PM Eastern

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time